WILSON JAMES N sold $1.1M of CORT (indirect holdings)
WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $111.43 ($110.49–$112.64, $1.11M total) across 3 trades on 2026-08-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed fact is the size, timing, and pricing range of the director’s open-market sale under a 10b5-1 plan; it does not include new corporate developments.
Market read
Traders may note insider selling activity, but the 10b5-1 structure and lack of new fundamentals suggest limited trading edge.
What to watch
The article does not disclose any change in company guidance, trial results, or financing needs; without those, the sale’s informational content is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported from an indirect holding by a director.
Ticker impact
Corcept Therapeutics Form 4 shows director Wilson James N sold 10,000 shares in open-market trades at about $110.49 to $112.64 on 2026-08-14.
Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around insider selling.
The filing is a routine 10b5-1 sale by a director, with no accompanying company-specific operational or financial catalyst disclosed in the text.
Market effects
No sector read-through is provided; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect planned liquidity rather than bearish expectations, so traders may overreact if they treat it as a signal.
Key entities
- issuerCORCEPT THERAPEUTICS INC
Company whose Form 4 insider sale is disclosed.
- insiderWILSON JAMES N
Director reporting an indirect open-market sale of 10,000 shares under a 10b5-1 plan.
